Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

Abstract

JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients < 30 years of age to 66.5% in patients ≥ 60 years of age; p < 0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p < 0.0001) and was not affected by prior immunosuppressant or natalizumab use.

Keywords

Multiple sclerosis JC virus natalizumab STRATIFY-JCV anti-JCV antibodies epidemiology infection risk international study antibody prevalence immunosuppressant therapy brain infection

Get full access to this article

View all access options for this article.

References

Tan

Koralnik

. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: Clinical features and pathogenesis. Lancet Neurol 2010; 9: 425–437.

Bloomgren

Richman

Hotermans

. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870–1880.

Gorelik

Lerner

Bixler

. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol 2010; 68: 295–303.

Bozic

Richman

Plavina

. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1. Ann Neurol 2011; 70: 742–750.

Bozic

Richman

Plavina

. Anti-JCV antibody prevalence in patients with relapsing multiple sclerosis receiving or considering treatment with natalizumab: baseline results of STRATIFY-2. Neurology 2012; 78: S41.002.

Trampe

Hemmelmann

Stroet

. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012; 78: 1736–1742.

Outteryck

Ongagna

Duhamel

. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. J Neurol 2012; 259: 2293–2298

Moiola

Sangalli

Martinelli

. Prevalence of anti-JCV antibodies in a cohort of natalizumab-treated multiple sclerosis patients from Italy. Neurology 2011; 76: A375. S30.007.

Subramanyam

Plavina

Simon

. Factors associated with anti-JCV antibody prevalence in large cohorts of natalizumab-treated MS patients. Mult Scler 2010; 16: S38–S39.

10.

Achiron

Chapman

Doleve

. Epidemiology of anti-JCV antibodies in Israeli multiple sclerosis population. In: American Academy of Neurology 64th Annual Meeting, New Orleans, LA, USA, 21 April–28 April 2012, presentation no. P02.138.